Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › FP7

READNA · REvolutionary Approaches and Devices for Nucleic Acid Analysis

FP7Status: CLOSED1 June 200830 November 2012EU funding €11,992,319

The REvolutionary Approaches and Devices for Nucleic Acid analysis – READNA – consortium is composed of researchers from 10 academic institutions, 5 SMEs and 3 large companies. The goals of the READNA consortium are to revolutionize nucleic acid analysis methods, by 1) improving elements necessary to use the currently emerging generation of nucleic acid sequencers in a meaningful and accessible way, 2) providing methods that allow in situ nucleic acid analysis and methods capable of selectively characterizing mutant DNA in a high background of wildtype DNA, 3) combining RNA and DNA analysis in a single analytical device, 4) providing technology to efficiently analyze DNA methylation (genome-wide, with high resolution and in its long-range context), 5) implementing novel concepts for high-throughput HLA-screening, 6) developing fully integrated solutions for mutational screening of small target regions (such as for screening newborns for cystic fibrosis mutations), 7) developing a device for screening multiple target regions with high accuracy, and 8) implementing strategies for effective and high-resolution genotyping of copy number variations. An important part of READNA is dedicated to the development of the next generation of nucleic analysis devices on individual DNA molecules by stretching out nucleic acid molecules in nanosystems, using alpha-hemolysing nanopores and carbon nanotubes. These approaches will benefit from improved interrogation and detection strategies which we will develop. Our methods and devices will boost the possibilities of genetic research by closing in on the target of 1000 Euros for the sequence of a complete human genome, while at the same time leading a revolution in cost-effective, non-invasive early screening for diseases such as cancer.

Consortium · 20 organisations

coordinator

COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES

FR · €2,112,971

participant

OXFORD NANOPORE TECHNOLOGIES LTD

UK · €730,000

participant

FUNDACIO PARC CIENTIFIC DE BARCELONA

ES · €514,040

participant

UPPSALA UNIVERSITET

SE · €764,960

participant

CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL

DE · €401,213

participant

PHOTONIS FRANCE SAS

FR · €74,700

participant

UNIVERSITY OF SOUTHAMPTON

UK · €460,243

participant

DANMARKS TEKNISKE UNIVERSITET

DK · €353,725

participant

PHILIPS ELECTRONICS NEDERLAND BV

NL · €18,250

participant

HUMMINGBIRD DIAGNOSTICS GMBH

DE · €166,605

participant

NAVINCI DIAGNOSTICS AB

SE · €599,076

participant

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

UK · €2,094,491

participant

MAX IV Laboratory, Lund University

SE

participant

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV

DE · €1,053,769

participant

UNIVERSITY OF LEICESTER

UK · €1,035,000

participant

GENEWAVE SAS

FR · €24,934

participant

LIFE TECHNOLOGIES GmbH

DE · €6,037

participant

FlexGen B.V.

NL · €100,000

participant

GOETEBORGS UNIVERSITET

SE · €549,986

participant

TECHNISCHE UNIVERSITEIT DELFT

NL · €932,318

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.